Valuable clinical indicators for identifying infantile-onset inflammatory bowel disease patients with monogenic diseases

BACKGROUND Infantile-onset inflammatory bowel disease (IO-IBD) occurs in very young children and causes severe clinical manifestations, which has poor responses to traditional inflammatory bowel disease (IBD) treatments. At present, there are no simple and reliable laboratory indicators for early screening IO-IBD patients, especially those in whom the disease is caused by monogenic diseases. AIM To search for valuable indicators for early identifying IO-IBD patients, especially those in whom the disease is caused by monogenic diseases. METHODS A retrospective analysis was performed in 73 patients with IO-IBD admitted to our hospital in the past 5 years. Based on the next-generation sequencing results, they were divided into a monogenic IBD group (M-IBD) and a non-monogenic IBD group (NM-IBD). Forty age-matched patients with allergic proctocolitis (AP) were included in a control group. The clinical manifestations and the inflammatory factors in peripheral blood were evaluated. Logistic regression analysis and receiver operating characteristic (ROC) curve analysis were used to identify the screening factors and cut-off values of IO-IBD as well as monogenic IO-IBD, respectively. RESULTS Among the 44 M-IBD patients, 35 carried IL-10RA mutations, and the most common mutations were c.301C>T (p.R101W, 30/70) and the c.537G>A (p.T179T, 17/70). Patients with higher serum tumor necrosis factor (TNF)-α value were more likely to have IBD [odds ratio (OR) = 1.25, 95% confidence interval (CI): 1.05-1.50, P = 0.013], while higher serum albumin level was associated with lower risk of IBD (OR = 0.86, 95%CI: 0.74-1.00, P = 0.048). The cut-off values of TNF-α and albumin were 17.40 pg/mL (sensitivity: 0.78; specificity: 0.88) and 36.50 g/L (sensitivity: 0.80; specificity: 0.90), respectively. The increased ferritin level was indicative of a genetic mutation in IO-IBD patients. Its cut-off value was 28.20 ng/mL (sensitivity: 0.93; specificity: 0.92). When interleukin (IL)-10 level was higher than 33.05 pg/mL (sensitivity: 1.00; specificity: 0.84), or the onset age was earlier than 0.21 mo (sensitivity: 0.82; specificity: 0.94), the presence of disease-causing mutations in IL-10RA in IO-IBD patients was strongly suggested. CONCLUSION Serum TNF-α and albumin level could differentiate IO-IBD patients from allergic proctocolitis patients, and serum ferritin and IL-10 levels are useful indicators for early diagnosing monogenic IO-IBD.

[1]  S. Rosenzweig,et al.  PI3K pathway defects leading to immunodeficiency and immune dysregulation , 2019, The Journal of allergy and clinical immunology.

[2]  Andrew J. Oler,et al.  Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease , 2019, The Journal of allergy and clinical immunology.

[3]  Ying Zhou,et al.  Phenotypic Characterization of Very Early-Onset Inflammatory Bowel Disease with Interleukin-10 Signaling Deficiency: Based on a Large Cohort Study. , 2018, Inflammatory bowel diseases.

[4]  Yan Guo,et al.  Analysis of clinical phenotype and genotype of 30 Chinese pediatric patients suffering very early onset inflammatory bowel disease , 2018 .

[5]  J. Carcillo,et al.  Hyperferritinemia and inflammation , 2017, International immunology.

[6]  Xiuyong Cheng,et al.  Mutations in Interleukin-10 Receptor and Clinical Phenotypes in Patients with Very Early Onset Inflammatory Bowel Disease: A Chinese VEO-IBD Collaboration Group Survey , 2017, Inflammatory bowel diseases.

[7]  S. Kugathasan,et al.  Nonclassic Inflammatory Bowel Disease in Young Infants: Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-Linked Syndrome, and Other Disorders. , 2017, Pediatric clinics of North America.

[8]  J. Carcillo,et al.  A Systemic Inflammation Mortality Risk Assessment Contingency Table for Severe Sepsis* , 2017, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

[9]  方伯梁,et al.  A systemic inflammation mortality risk assessment contingency table for severe sepsis , 2017 .

[10]  N. Sebire,et al.  Phenotypic and Genotypic Characterisation of Inflammatory Bowel Disease Presenting Before the Age of 2 years , 2017, Journal of Crohn's & colitis.

[11]  Yan Guo,et al.  Comprehensive mutation screening for 10 genes in Chinese patients suffering very early onset inflammatory bowel disease. , 2016, World journal of gastroenterology.

[12]  H. Takada,et al.  Novel exonic mutation inducing aberrant splicing in the IL10RA gene and resulting in infantile-onset inflammatory bowel disease: a case report , 2016, BMC Gastroenterology.

[13]  H. Zeng,et al.  [Interleukin-10 receptor mutations in children with neonatal onset inflammatory bowel disease: genetic diagnosis and pathogenesis]. , 2015, Zhonghua er ke za zhi = Chinese journal of pediatrics.

[14]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[15]  S. Snapper,et al.  Incidence, outcomes, and health services burden of very early onset inflammatory bowel disease. , 2014, Gastroenterology.

[16]  Pingbo Zhang,et al.  Suppression of immunoglobulin production in human peripheral blood mononuclear cells by monocytes via secretion of heavy-chain ferritin. , 2014, Immunobiology.

[17]  D. Miranda-Saavedra,et al.  The IL-10/STAT3-mediated anti-inflammatory response: recent developments and future challenges , 2013, Briefings in functional genomics.

[18]  J. Puchalka,et al.  Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. , 2012, Gastroenterology.

[19]  M. C. Castiello,et al.  Autoimmunity in Wiskott–Aldrich Syndrome: An Unsolved Enigma , 2012, Front. Immun..

[20]  T. Heike,et al.  Successful Treatment with Infliximab for Inflammatory Colitis in a Patient with X-linked Anhidrotic Ectodermal Dysplasia with Immunodeficiency , 2012, Journal of Clinical Immunology.

[21]  K. Schwarz,et al.  Clinical and immunological manifestations of patients with atypical severe combined immunodeficiency. , 2011, Clinical immunology.

[22]  A. Salas,et al.  Apoptosis resistance of mucosal lymphocytes and IL‐10 deficiency in patients with steroid‐refractory Crohn's disease , 2011, Inflammatory bowel diseases.

[23]  A. Schäffer,et al.  Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. , 2009, The New England journal of medicine.

[24]  T. To,et al.  Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data , 2009, Gut.

[25]  J. Steinke,et al.  The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. , 2008, The Journal of allergy and clinical immunology.

[26]  P. Arosio,et al.  New functions for an iron storage protein: the role of ferritin in immunity and autoimmunity. , 2008, Journal of autoimmunity.

[27]  D. Lacks,et al.  Ferritin levels in children with severe sepsis and septic shock , 2007, Acta paediatrica.

[28]  Jingwu Z. Zhang,et al.  Chemokine CXCL12 Induces Binding of Ferritin Heavy Chain to the Chemokine Receptor CXCR4, Alters CXCR4 Signaling, and Induces Phosphorylation and Nuclear Translocation of Ferritin Heavy Chain* , 2006, Journal of Biological Chemistry.

[29]  R. Baldassano,et al.  Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. , 2005, The Journal of pediatrics.

[30]  J. Orange,et al.  The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. , 2004, The Journal of allergy and clinical immunology.

[31]  P. Hersey,et al.  Dendritic Cells Heavy Chain Ferritin Activates Regulatory T Cells by Induction of Changes In , 2022 .

[32]  J. Piette,et al.  Diagnostic value of ferritin and glycosylated ferritin in adult onset Still's disease. , 2001, The Journal of rheumatology.

[33]  D. Goldblatt,et al.  Colitis in chronic granulomatous disease , 2001, Archives of disease in childhood.

[34]  I. Gérin,et al.  Sequence of a putative glucose 6‐phosphate translocase, mutated in glycogen storage disease type Ib 1 , 1997, FEBS letters.

[35]  A. Fischer,et al.  Clinical spectrum of X-linked hyper-IgM syndrome. , 1997, The Journal of pediatrics.

[36]  B. Brando,et al.  Specific binding sites for H-ferritin on human lymphocytes: modulation during cellular proliferation and potential implication in cell growth control. , 1991, Blood.

[37]  D. Williams,et al.  Suppressive effects in vivo of purified recombinant human H-subunit (acidic) ferritin on murine myelopoiesis. , 1989, Blood.